Repligen (RGEN) Dropped Following the Earnings Release

In its first-quarter 2026 capitalist letter, The Brown Capital Management Small Company Fund highlighted stocks similar Repligen Corporation (NASDAQ:RGEN). Repligen Corporation (NASDAQ:RGEN) is simply a beingness subject institution that develops and distributes bioprocessing technologies and systems. On June 23, 2026, Repligen Corporation (NASDAQ:RGEN) closed astatine $126.37 per share. One-month instrumentality of Repligen Corporation (NASDAQ:RGEN) was 11.66%, and its shares gained 1.89% implicit the past 52 weeks. Repligen Corporation (NASDAQ:RGEN) has a marketplace capitalization of $7.13 billion.

The Brown Capital Management Small Company Fund stated the pursuing regarding Repligen Corporation (NASDAQ:RGEN) successful its Q1 2026 capitalist letter:

"Among the apical detractors to show successful the archetypal 4th of 2026 was Repligen Corporation (NASDAQ:RGEN). Repligen Corporation is simply a life-sciences institution that develops and manufactures products utilized passim the analyzable process of making biologic drugs, helping its customers summation ratio and trim costs. Biological drugs marque up astir a 4th of the wide pharmaceutical market, and biologics income are increasing successful the precocious single-digits, astatine astir treble the complaint of the wide pharmaceutical industry. Repligen's products are utilized successful the process of manufacturing hundreds of biologic drugs successful assorted phases, helping customers summation ratio and trim costs. Given its divers lawsuit base, we judge Repligen is well-positioned to payment from the increasing fig of biologic drugs being developed and commercialized, careless of which circumstantial drugs upwind up being successful. In summation to serving a increasing market, Repligen offers differentiated products successful markets wherever the larger vendors person failed to innovate. The institution is besides expanding its portfolio with strategical M&A and integrated innovation.

During the archetypal 4th of 2026, Repligen's banal terms declined steadily and past dropped sharply pursuing the Feb. 24 net release. The marketplace reacted poorly to Repligen's archetypal 2026 fiscal guidance. Management guided for 10% to 14% reported gross maturation and 9% to 13% integrated maturation for the afloat twelvemonth 2026. This outlook signaled a maturation deceleration compared to the 14% integrated maturation achieved successful the 4th quarter, prompting further terms weakness. Given the company's semipermanent opportunities, we spot this arsenic an overreaction and inactive presumption Repligen arsenic an EGC."